Tango Therapeutics/$TNGX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tango Therapeutics
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
Ticker
$TNGX
Sector
Primary listing
Employees
155
Headquarters
Website
TNGX Metrics
BasicAdvanced
$811M
-
-$1.32
1.64
-
Price and volume
Market cap
$811M
Beta
1.64
52-week high
$8.80
52-week low
$1.03
Average daily volume
2.2M
Financial strength
Current ratio
4.75
Quick ratio
4.517
Long term debt to equity
24.063
Total debt to equity
25.941
Profitability
EBITDA (TTM)
-154.796
Gross margin (TTM)
-461.61%
Net profit margin (TTM)
-599.14%
Operating margin (TTM)
-647.37%
Effective tax rate (TTM)
-0.12%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
-31.74%
Return on equity (TTM)
-76.09%
Valuation
Price to revenue (TTM)
33.044
Price to book
5.99
Price to tangible book (TTM)
5.99
Price to free cash flow (TTM)
-5.382
Free cash flow yield (TTM)
-18.58%
Free cash flow per share (TTM)
-1.354
Growth
Revenue change (TTM)
-42.85%
Earnings per share change (TTM)
18.89%
3-year revenue growth (CAGR)
0.36%
3-year earnings per share growth (CAGR)
6.35%
What the Analysts think about TNGX
Analyst ratings (Buy, Hold, Sell) for Tango Therapeutics stock.
Bulls say / Bears say
Cash runway extended into Q1 2027 by reducing preclinical spending and postponing selected combination studies, strengthening financial stability for core programs (FiercePharma)
First patient dosed in the Phase 1/2 trial combining TNG462 with Revolution Medicines’ daraxonrasib and zoldonrasib, advancing a key collaboration strategy (GlobeNewswire)
TNG456, a next-generation brain-penetrant PRMT5 inhibitor for MTAP-deleted glioblastoma, has begun Phase 1/2 dosing, translating strong preclinical CNS exposure into clinical advancement (GlobeNewswire)
Net loss widened 5.2% year-over-year to $39.9 million in Q1 2025, or $0.36 per share, missing consensus and underlining continued high cash burn (Zacks via Nasdaq)
Collaboration revenue fell 17% to $5.4 million in Q1 2025 from $6.5 million a year earlier, indicating weakness in partnership-driven income (GlobeNewswire)
Around 20% of employees were laid off in April 2025 to extend the cash runway, raising concerns about potential talent loss and operational capacity (BioPharma Dive)
Data summarised monthly by Lightyear AI. Last updated on 5 Oct 2025.
TNGX Financial Performance
Revenues and expenses
TNGX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Tango Therapeutics stock?
Tango Therapeutics (TNGX) has a market cap of $811M as of October 08, 2025.
What is the P/E ratio for Tango Therapeutics stock?
The price to earnings (P/E) ratio for Tango Therapeutics (TNGX) stock is 0 as of October 08, 2025.
Does Tango Therapeutics stock pay dividends?
No, Tango Therapeutics (TNGX) stock does not pay dividends to its shareholders as of October 08, 2025.
When is the next Tango Therapeutics dividend payment date?
Tango Therapeutics (TNGX) stock does not pay dividends to its shareholders.
What is the beta indicator for Tango Therapeutics?
Tango Therapeutics (TNGX) has a beta rating of 1.64. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.